Cargando…
The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
SIMPLE SUMMARY: Pancreatic ductal adenocarcinoma is a leading cause of cancer death worldwide. Due to the frequently late diagnosis, early metastasis and high therapy resistance curation is rare and prognosis remains poor overall. To provide early diagnostic and therapeutic predictors, various molec...
Autores principales: | Sturm, Niklas, Ettrich, Thomas J., Perkhofer, Lukas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750069/ https://www.ncbi.nlm.nih.gov/pubmed/35008381 http://dx.doi.org/10.3390/cancers14010217 |
Ejemplares similares
-
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions
por: Sturm, Niklas, et al.
Publicado: (2022) -
Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Kim, Hongbeom, et al.
Publicado: (2020) -
DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma
por: Ettrich, Thomas J., et al.
Publicado: (2016) -
Tailor‐Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma
por: Hu, Xi, et al.
Publicado: (2021) -
Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma
por: Karimnia, Vida, et al.
Publicado: (2021)